This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Breast feeding after medical termination of pregnancy

Authoring team

Medically terminating a pregnancy during breastfeeding

Mifepristone and misoprostol are recommended for medical termination of pregnancy (abortion) (1)

  • are often given as single doses, with mifepristone being administered first, followed by misoprostol; although further doses of misoprostol may be required.
  • as there are negligible amounts for each medicine found in breast milk and the risk of accumulation in the infant is minimal, they are considered compatible with breast feeding.
  • there are no data on the direct effect of mifepristone or misoprostol on the lactation process.
  • gemeprost is no longer routinely recommended
  • a review states that breastfeeding and multi-fetal pregnancies are not contraindications to medical termination (2)
  • previous guidance stated that as a precaution,infants exposed to mifepristone or misoprostol via breastmilk should be monitored for nausea, vomiting and poor feeding (3)

Mifepristone use in breasfeeding:

  • use with caution
    • mifepristone can be used during breastfeeding due to negligible levels in milk.
    • infant monitoring
      • as a precaution, monitor the infant for nausea, vomiting, diarrhoea and poor feeding.
    • further information
      • limited data suggest that the levels of mifepristone in milk are negligible when single doses of up to 600mg have been administered
        • breastfeeding can continue in an uninterrupted manner during medical termination.
      • no side effects have been reported for infants after exposure to mifepristone via breast milk

Misoprostol use in breastfeeding

  • use with caution
    • misoprostol can be used during breastfeeding due to negligible levels in milk.
    • infant monitoring
      • as a precaution, monitor the infant for nausea, vomiting, diarrhoea and poor feeding.
    • further information
      • oral misoprostol is excreted into breast milk in negligible to very small amounts when doses up to 600mg have been administered, which are rapidly eliminated.
      • although there is no evidence for vaginal or rectal administration, similar low levels are anticipated in breast milk.
  • no interruption of breastfeeding is necessary when misoprostol is given by any route, or if repeated doses are required in the short term
  • no side effects have been reported for infants after exposure to misoprostol via breast milk

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.